Umberto Tosi1, Omri Maayan1, Anjile An2, Miguel E Tusa Lavieri1, Sergio W Guadix1, Antonio P DeRosa3, Paul J Christos2, Susan Pannullo1, Philip E Stieg1, Andrew Brandmaier4, Jonathan P S Knisely4, Rohan Ramakrishna5. 1. Department of Neurological Surgery, Weill Cornell Medicine, 525 E. 68th St.10065, Box 99, New York, NY, USA. 2. Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, USA. 3. Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medicine, New York, NY, USA. 4. Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. 5. Department of Neurological Surgery, Weill Cornell Medicine, 525 E. 68th St.10065, Box 99, New York, NY, USA. Ror9068@med.cornell.edu.
Abstract
INTRODUCTION: Neurofibromatosis type 2 (NF2) is characterized by often bilateral vestibular schwannomas (VS) that result in progressive hearing loss and compression of nearby brainstem structures causing cranial nerve palsies. Treatment of these tumors remains challenging, as both surgical removal and expectant management can result in symptom progression. Stereotactic radiosurgery (SRS) has been investigated for the management of NF2-associated VS; however, the role, promises, and pitfalls of this treatment modality remain unclear. METHODS: Ovid MEDLINE, EMBASE, Web of Science, and Cochrane Reviews were searched for studies assessing SRS outcome in NF2-associated VS only. Primary endpoints included tumor control, serviceable hearing, presence of tinnitus, and cranial nerve V and VII symptoms. RESULTS: A total of 16 studies (589 patients harboring 750 tumors) were analyzed. Clinical tumor control was achieved in 88% of cases (95% CI 80-95%); salvage surgery was needed in 8% (95% CI 4-13%) of cases. Treatment resulted in a worsening of pre-treatment serviceable hearing (OR = 0.26, p < 0.01), increased facial nerve (OR = 1.62, p < 0.01) and trigeminal nerve (OR = 1.42, p = 0.07) impairment. The incidence of vestibular symptoms and hydrocephalus were not consistently reported and thus could not be assessed. CONCLUSIONS: The treatment of NF2-associated VS continues to pose a challenge, as current SRS regimens result in impaired hearing and worse cranial nerve comorbidities, despite achieving high tumor control. It remains unclear if these findings have to be regarded as treatment complications or, rather, continued disease progression.
INTRODUCTION: Neurofibromatosis type 2 (NF2) is characterized by often bilateral vestibular schwannomas (VS) that result in progressive hearing loss and compression of nearby brainstem structures causing cranial nerve palsies. Treatment of these tumors remains challenging, as both surgical removal and expectant management can result in symptom progression. Stereotactic radiosurgery (SRS) has been investigated for the management of NF2-associated VS; however, the role, promises, and pitfalls of this treatment modality remain unclear. METHODS: Ovid MEDLINE, EMBASE, Web of Science, and Cochrane Reviews were searched for studies assessing SRS outcome in NF2-associated VS only. Primary endpoints included tumor control, serviceable hearing, presence of tinnitus, and cranial nerve V and VII symptoms. RESULTS: A total of 16 studies (589 patients harboring 750 tumors) were analyzed. Clinical tumor control was achieved in 88% of cases (95% CI 80-95%); salvage surgery was needed in 8% (95% CI 4-13%) of cases. Treatment resulted in a worsening of pre-treatment serviceable hearing (OR = 0.26, p < 0.01), increased facial nerve (OR = 1.62, p < 0.01) and trigeminal nerve (OR = 1.42, p = 0.07) impairment. The incidence of vestibular symptoms and hydrocephalus were not consistently reported and thus could not be assessed. CONCLUSIONS: The treatment of NF2-associated VS continues to pose a challenge, as current SRS regimens result in impaired hearing and worse cranial nerve comorbidities, despite achieving high tumor control. It remains unclear if these findings have to be regarded as treatment complications or, rather, continued disease progression.
Authors: Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser Journal: Lancet Date: 2009-05-22 Impact factor: 79.321
Authors: M Ruggieri; P Iannetti; A Polizzi; I La Mantia; A Spalice; O Giliberto; N Platania; A L Gabriele; V Albanese; L Pavone Journal: Neuropediatrics Date: 2005-02 Impact factor: 1.947
Authors: D Gareth R Evans; Anthony Moran; Andrew King; S Saeed; Nihal Gurusinghe; Richard Ramsden Journal: Otol Neurotol Date: 2005-01 Impact factor: 2.311
Authors: Hildegard Kehrer-Sawatzki; Lan Kluwe; Reinhard E Friedrich; Anna Summerer; Eleonora Schäfer; Ute Wahlländer; Cordula Matthies; Isabel Gugel; Said Farschtschi; Christian Hagel; David N Cooper; Victor-Felix Mautner Journal: Hum Genet Date: 2018-07-13 Impact factor: 4.132
Authors: Alvin T deTorres; Carmen C Brewer; Chris K Zalewski; Kelly A King; Robert Walker; Gretchen C Scott; Ashok R Asthagiri; Prashant Chittiboina; Hung Jeffrey Kim Journal: Otol Neurotol Date: 2018-03 Impact factor: 2.311
Authors: Scott R Plotkin; Miriam A Bredella; Wenli Cai; Ara Kassarjian; Gordon J Harris; Sonia Esparza; Vanessa L Merker; Lance L Munn; Alona Muzikansky; Manor Askenazi; Rosa Nguyen; Ralph Wenzel; Victor F Mautner Journal: PLoS One Date: 2012-04-27 Impact factor: 3.240
Authors: Junhyung Kim; Yukyeng Byeon; Sang Woo Song; Young Hyun Cho; Chang-Ki Hong; Seok Ho Hong; Jeong Hoon Kim; Do Heui Lee; Ji Eun Park; Ho Sung Kim; Young-Hoon Kim Journal: Front Oncol Date: 2022-09-16 Impact factor: 5.738